ATYR PHARMA, INC. (NASDAQ:LIFE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Loan and Security Agreement

On June 30, 2017, aTyr Pharma, Inc. (the “Company”) entered into the First Amendment (the “Loan Amendment”) to the Loan and Security Agreement with Silicon Valley Bank (“SVB”) and Solar Capital Ltd. (“Solar”, and together with SVB, the “Lenders”). The Loan Amendment amends that certain Loan and Security Agreement between the Company and the Lenders, dated as of November 18, 2016 (the “Loan Agreement”).

The Loan Amendment modifies certain conditions under which the Company may receive and repay term loans under the Loan Agreement, which provides for up to $20.0 million in term loans in three tranches. The Loan Amendment provides that (i) up to $5.0 million in the second tranche of term loans may be drawn down by the Company at any time before the earlier of June 30, 2017 or an event of default, at the Company’s discretion, which term loans are no longer subject to achievement of certain milestones, and (ii) an additional $5.0 million in the third tranche of term loans may be drawn down by the Company at any time after June 30, 2017 and before the earlier of December 31, 2017 or an event of default, at the Company’s discretion, subject to achievement of certain milestones.In connection with the Loan Amendment, the second tranche of $5.0 million was funded on June 30, 2017.If the Company fails to meet certain milestones set forth in the Loan Amendment by August 31, 2017, then the Company will be required to secure the second tranche term loans with cash until such time that those milestones are met.If such milestones are not met by October 31, 2017, the Company will have the option to maintain the cash security for the second tranche term loans or pre-pay the second tranche term loans.

The foregoing is only a brief description of the Loan Agreement and the Loan Amendment, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the Loan Agreement and the Loan Amendment. The Loan Agreement was previously filed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the Loan Amendment will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017.

Warrants

As previously disclosed, in connection with the Loan Agreement, the Company agreed to issue warrants to each of SVB and Solar to purchase that number of shares of the Company’s common stock equal to 3% of the amount loaned under the Loan Agreement by SVB and Solar, respectively, or $75,000, divided by the lesser of (i) the average closing price of the Company’s common stock for the 10 trading days prior to the date of issuance of the warrants and (ii) the closing price of the Company’s common stock on the date prior to the date of issuance of the warrants in connection with the Company’s draw down of the second tranche under the Loan Agreement (the “Warrants”). The number of shares for each Warrant is 20,833 shares and the exercise price for each Warrant is $3.60 per share. The Warrants are immediately exercisable and will expire on June 30, 2024, provided that such Warrants have not been previously exercised or have expired in connection with certain fundamental transactions involving the Company.

The foregoing is only a brief description of the Warrants, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the Warrants which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017.

Item 1.01 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 of this Current Report on Form8-K is hereby incorporated by reference in this Item 1.01.

Item 1.01 Unregistered Sales of Equity Securities.

The information contained in Item 1.01 of this Current Report on Form8-K is hereby incorporated by reference in this Item 1.01.

The Warrants described in Item 1.01 above were offered and sold in reliance upon the exemption from registration provided by Section4(a)(2) under the Securities Act of 1933, as amended (the “Securities Act”). The Warrants contain representations to support the Company’s reasonable belief that each of the recipients of such securities had access to information concerning the Company’s operations and financial condition, that each such recipient is acquiring the securities for its own account and not with a view to the distribution thereof, and that each such recipient is an “accredited investor” as defined by Rule 501 promulgated under the Securities Act.

About ATYR PHARMA, INC. (NASDAQ:LIFE)

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.